Literature DB >> 12144536

Intracellular T cell cytokines in patients with B cell chronic lymphocytic leukaemia (B-CLL).

Eva D Rossmann1, Nongnit Lewin, Mahmood Jeddi-Tehrani, Anders Osterborg, Håkan Mellstedt.   

Abstract

Analysis of cytokine production is a tool to functionally characterise T cells. In this study, spontaneous and polyclonal activation induced cytokine production in T cells were assessed by flow cytometry in patients with B-CLL. Patients with progressive disease had a significantly increased number of T cells spontaneously producing IL-2, IL-4 and GM-CSF as compared to healthy donors and patients with non-progressive CLL, which was not the case for TNF-alpha and IFN-gamma producing T cells. However, no difference in the frequency of T cells producing these cytokines was seen comparing patients with non-progressive disease to control donors. Polyclonal activation of B-CLL T cells in vitro induced an increased proportion of T cells producing these five cytokines in patients as well as in control donors, indicating that T cells in CLL patients might have a relatively well preserved functional capacity. However, the increase in GM-CSF, TNF-alpha and IL-4 producing T cells was more marked in CLL patients than in controls. Furthermore, following activation, a higher frequency of cytokine-producing T cells was noted in patients with progressive disease as compared to those with non-progressive disease. The augmented number of cytokine-producing T cells in CLL may indicate an up-regulated capability of T cells to secrete cytokines, especially in patients with progressive CLL. The increased production of the T cell derived cytokines GM-CSF, TNF-alpha, IL-4 and IL-2 is interesting, as these cytokines have previously been shown to support growth of B-CLL leukaemic cells in vitro and as T cells might specifically recognise the autologous leukaemic B cells in vivo. The findings may suggest a role for T cells in the pathogenesis of B-CLL.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12144536     DOI: 10.1034/j.1600-0609.2002.01612.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  16 in total

1.  Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers.

Authors:  Jason A Dubovsky; Daniel Wang; John J Powers; Emmanuel Berchmans; Matthew A Smith; Kenneth L Wright; Eduardo M Sotomayor; Javier A Pinilla-Ibarz
Journal:  Leuk Res       Date:  2010-09-22       Impact factor: 3.156

2.  Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia (B-CLL): comparison of indolent and progressive disease.

Authors:  Shahryar Kiaii; Aniruddha Choudhury; Fariba Mozaffari; Eva Kimby; Anders Osterborg; Håkan Mellstedt
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

3.  Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells.

Authors:  Güllü Görgün; Tobias A W Holderried; David Zahrieh; Donna Neuberg; John G Gribben
Journal:  J Clin Invest       Date:  2005-06-16       Impact factor: 14.808

4.  Cytokine Release Ensuing Interaction Between Human Peripheral Blood Mononuclears and Epstein-Barr Virus Transformed B-CLL Cell Line.

Authors:  Hanna Bessler; Chiya Moshe Leibovitch; Meir Djaldetti
Journal:  J Immunother Precis Oncol       Date:  2020-04-28

5.  The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.

Authors:  Matthew D Blunt; Stefan Koehrer; Rachel C Dobson; Marta Larrayoz; Sarah Wilmore; Alice Hayman; Jack Parnell; Lindsay D Smith; Andrew Davies; Peter W M Johnson; Pamela B Conley; Anjali Pandey; Jonathan C Strefford; Freda K Stevenson; Graham Packham; Francesco Forconi; Greg P Coffey; Jan A Burger; Andrew J Steele
Journal:  Clin Cancer Res       Date:  2016-10-03       Impact factor: 12.531

6.  IFN gamma gene polymorphism may contribute to the susceptibility to CLL.

Authors:  Iwona Urbanowicz; Grzegorz Mazur; Jolanta Stacherzak-Pawlik; Katarzyna Bogunia-Kubik; Tomasz Wróbel; Mieczysław Woźniak; Kazimierz Kuliczkowski
Journal:  Pathol Oncol Res       Date:  2009-09-15       Impact factor: 3.201

7.  High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.

Authors:  Sina Oppermann; Jarkko Ylanko; Yonghong Shi; Santosh Hariharan; Christopher C Oakes; Patrick M Brauer; Juan C Zúñiga-Pflücker; Brian Leber; David E Spaner; David W Andrews
Journal:  Blood       Date:  2016-06-13       Impact factor: 22.113

8.  IL-4 rescues surface IgM expression in chronic lymphocytic leukemia.

Authors:  Benchang Guo; Lu Zhang; Nicholas Chiorazzi; Thomas L Rothstein
Journal:  Blood       Date:  2016-05-25       Impact factor: 22.113

9.  CTLA-4 affects expression of key cell cycle regulators of G0/G1 phase in neoplastic lymphocytes from patients with chronic lymphocytic leukaemia.

Authors:  Lidia Ciszak; Irena Frydecka; Dariusz Wolowiec; Aleksandra Szteblich; Agata Kosmaczewska
Journal:  Clin Exp Med       Date:  2015-05-24       Impact factor: 3.984

10.  Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma.

Authors:  Egil S Blix; Jonathan M Irish; Anne Husebekk; Jan Delabie; Lise Forfang; Anne M Tierens; June H Myklebust; Arne Kolstad
Journal:  BMC Cancer       Date:  2012-10-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.